Comparing antibiotic choices for liver transplant patients with resistant bacteria
Treatments studied
This study compares two ways of giving preventive antibiotics to liver transplant patients who carry resistant bacteria. The goal is to see if targeted antibiotics work better than standard ones at preventing infections without causing more side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are scheduled for a liver transplant
- You have tested positive for a type of resistant bacteria in your body (this is called CPE)
- You do not currently have an active infection from this bacteria
- You do not have a known allergy to the antibiotics used in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
This study compares two strong antibiotics—ceftazidime-avibactam and a high dose of meropenem given over a longer infusion—in patients with advanced liver disease who develop a hospital-acquired infection. The goal is to see which works better and is safer.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This study tests a precise dosing approach for the antibiotic ceftazidime-avibactam to treat serious infections in ICU patients. It aims to help people with hard-to-treat bacteria that are resistant to many other antibiotics.
This trial tests whether giving the antibiotic ceftazidime-avibactam continuously or intermittently works better for ICU patients with severe infections caused by drug-resistant bacteria. The goal is to see which method improves outcomes.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.